CD8A and inflammatory bowel disease: Our findings also are important in that by defining agonistic peptides for both class Ia and class Ib MHC-restricted CD8+ Tregs, we provide a unique biologics or synthetic chemistry opportunity for potential novel therapeutics for IBD.